BRIEF—Napp launches Pelmeg in the UK

Today, Napp Pharmaceuticals, part of the Mundipharma global network of independent associated companies, announced the UK launch of its pegfilgrastim biosimilar Pelmeg, its first biosimilar to be launched in partnership with Cinfa Biotech.

This announcement follows the European Commission’s approval of Pelmeg, a biosimilar to Amgen’s Neulasta, in November 2018.

Mundipharma began launching Pelmeg in Europe earlier this month, and it is now available in Germany, the Netherlands and Ireland.

Pelmeg is indicated for the reduction in the duration of neutropenia and incidence of febrile neutropenia (FN) in adults treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukemia and myelodysplastic syndromes).

Pelmeg is a self-administered, single dose formulation and a lower drug cost alternative to the existing long-acting option Neulasta.